Friday, July 17, 2015 12:03:31 AM
For those of you interested in TA, I thought I would take some time to post my findings, considering the potential for this stock to gap up in next coming days. With the public offering closing on 7/17/2015 combined with the fact that PPS is steadily climbing from offer price, this stock is on radar of many short term and long term investors alike.
a) On 30 min/1 hour chart, we are starting to witness trend change (supporting Bulls). Many indicators confirm this change today.
b) The daily chart is showing bearish symptoms, but considering the offering made by TNXP, this statement shouldn’t come as surprise. Bullish shorter time frame chart ( like 30 min/1 hr ) is expected to reverse some of the indicators on daily chart ( to bullish ) in next few days.
c) Looking at RSI levels ,some may consider the stock to be overbought in shorter time frames and therefore expect pull back to happen. Considering the daily chart to be close to oversold levels, this stock can gap up faster to higher pps if it wants, and consolidate later. RSI indicator for this stock would be of little importance, given this stock's past performance.(RSI had gone down to '2' on 10/16/14, '93' on 1/13/14. Also noting bigger time periods where RSI stayed below 25 or above 80 ).
d) 7.8ish area would act as our strong support area.
e) 8.2 – 8.5 have tons of resistances, MA50 lines, Fib lines etc. 8.8ish and 9.3ish form the next resistance zones.
f) The big fluctuation on prices should be expected for this stock, and should be considered normal.
g) With that said, the most important observation that cannot be ignored is that the chart matches the fundamental aspects of this stock, and appears to be bullish short or long term.
I can be completely wrong here.
Always have a plan, trade smart, and good luck.
Recent TNXP News
- Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024 • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:05:23 PM
- Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS) • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024 • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/14/2024 09:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:24:27 PM
- Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/13/2024 09:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/12/2024 09:01:03 PM
- Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/12/2024 01:00:00 PM
- Tonix Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 06/11/2024 09:17:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/11/2024 08:49:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 12:53:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:21:23 PM
- Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split • GlobeNewswire Inc. • 06/06/2024 03:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:05:39 PM
- Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024 • GlobeNewswire Inc. • 06/06/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024 • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:05:27 PM
- Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 12:05:48 PM
- Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024 • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 09:10:58 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM